Alpha 2.0
Login Register
» Articles » PMID: 32359098

Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot

Overview
Journal Headache
Publisher Wiley
Specialties Neurology
Psychiatry
Date 2020 May 3
PMID 32359098
Citations 12
Authors
Ashhar Ali
Affiliations
Soon will be listed here.
Abstract

The COVID-19 pandemic has undoubtedly changed our practice of medicine. With our collective resources and attention focused on caring for those afflicted with the disease, other medical conditions have temporarily but understandably faced constraint. For migraine patients who often require in-person visits for infusions and procedures, this has become particularly challenging. Here, we share our experience in navigating this exigency amidst a local surge of COVID-19.

Citing Articles

Impact of delaying botulinum toxin treatment in patients with migraine during the COVID-19 pandemic.

Nascimento H, Videira G, Duarte S, Correia C, Andrade C Arq Neuropsiquiatr. 2023; 81(3):248-252.

PMID: 37059434 PMC: 10104750. DOI: 10.1055/s-0043-1763490.

Post-COVID Headache: A Literature Review.

Chhabra N, Grill M, Halker Singh R Curr Pain Headache Rep. 2022; 26(11):835-842.

PMID: 36197571 PMC: 9533267. DOI: 10.1007/s11916-022-01086-y.

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine.

Kubota G Arq Neuropsiquiatr. 2022; 80(5 Suppl 1):218-226.

PMID: 35976302 PMC: 9491437. DOI: 10.1590/0004-282X-ANP-2022-S112.

COVID-19 effect on perioperative findings of flexible/semi-rigid ureterorenoscopic lithotripsy: A match-pair analysis.

Demirci A, Hizli F, Basar H Urologia. 2022; 90(1):109-115.

PMID: 35445621 PMC: 10076157. DOI: 10.1177/03915603221093719.

[Adaptation of headache units in Andalusia to the COVID-19 pandemic. Analysis of the Andalusian Neurology Society's Headache Study Group].

Lamas-Perez R, Viguera-Romero F, Sanchez-Caballero F, Martinez-Simon J, Gomez-Camello A, Gonzalez-Oria C Rev Neurol. 2022; 74(2):55-60.

PMID: 35014020 PMC: 11500027. DOI: 10.33588/rn.7402.2021258.

References
1.
Lipton R, Varon S, Grosberg B, McAllister P, Freitag F, Aurora S . OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology. 2011; 77(15):1465-72. DOI: 10.1212/WNL.0b013e318232ab65. View
2.
Onder G, Rezza G, Brusaferro S . Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020; 323(18):1775-1776. DOI: 10.1001/jama.2020.4683. View
3.
Day M . Covid-19: European drugs agency to review safety of ibuprofen. BMJ. 2020; 368:m1168. DOI: 10.1136/bmj.m1168. View
4.
Santoro A, Copetti M, Miscio A, Leone M, Fontana A . Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurol Sci. 2020; 41(7):1809-1820. PMC: 7359167. DOI: 10.1007/s10072-020-04283-y. View
5.
. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(12):343-346. PMC: 7725513. DOI: 10.15585/mmwr.mm6912e2. View